The Federal Trade Commission and State of New York late last month filed a lawsuit against Martin Shkreli, charging that Shkreli and Vyera Pharmaceuticals raised the price of the life-saving drug Daraprim by more than 4,000% and worked to corner the market for such drugs.
“The joint action accused Shkreli and Vyera Pharmaceuticals, formerly known as Turing Pharmaceuticals, of scheming to ‘illegally’ prevent would-be generic competitors from selling a version of Daraprim,” as Stat’s Ed Silverman reported on Jan. 27. After acquiring the drug in 2015, Shkreli, dubbed the “Pharma Bro,” and Turing raised the list price of the medication from $17.50 per tablet to $750, he added. Continue reading →
One question Julie Appleby posed to a panel she moderated on the high cost of prescription drugs was simple enough: Do drug pricing reform efforts promise consumer relief?
The answer from three experts Appleby assembled for a panel discussion at Health Journalism 2019 this month in Baltimore was that, yes, efforts in Congress could provide some relief and those efforts have bipartisan support. But, as with any pending legislation, the details in the final bills will matter. Also, of course, any bill needs to pass both houses and then President Trump would need to sign it. Continue reading →
By Alvesgaspar – Own work, CC BY-SA 3.0, LinkReporter David Abel was denied access to talk to the Massachusetts state ornithologist about barn swallows.
David Abel had had enough.
The Boston Globe’s environmental writer was used to being denied interviews with state scientists and officials. But this latest refusal from the administration of Massachusetts Governor Charlie Baker was just too absurd.
Abel had been forbidden to speak with the state ornithologist. (Yes, this is Massachusetts, we have such an official.) His topic was not politically sensitive. Continue reading →
Cynthia Craft (@cynthiahcraft) is the director of engagement for AHCJ, joining the organization after an extensive career in daily journalism, including a decade on the health care beat. Craft most recently worked as a senior writer at The Sacramento Bee, having also worked for the Los Angeles Times, Dallas Times Herald and the California Journal.
Drawn by an influential lineup of speakers and panels – plus an intriguing offering of field trips – more than 800 conference-goers helped make AHCJ’s Health Journalism 2019 in Baltimore a record-setter in attendance.
In AHCJ’s 20 years of annual conferences, the increase in attendance has mirrored the public’s level of interest in health news and need for clear, accurate health care reporting. Today, health-care pocketbook issues, partisan politics and worrisome matters such as the re-emergence of measles and stubborn drug dependence epidemics are seen as topics likely to be front and center in upcoming elections.
From May 2 to May 5, health journalists attended more than 60 panels, including a carefully curated lineup guiding independent journalists toward success and informative sessions on how to cover aspects of the scientific revolution of genetics.
One of the best sessions at Health Journalism 2019 in Baltimore was the panel discussion about drug prices on May 3, “Of price spikes and shortages: New initiatives to increase patient access to generic and biosimilar drugs.” Wendy Wolfson, an independent journalist from Irvine, Calif., moderated the discussion.
Perhaps the most interesting of the four panel members was Martin Van Trieste, president and CEO, Civica Rx, a nonprofit manufacturer of generic drugs for hospitalized patients. Seven of the nation’s largest health systems have invested in Civica and their representatives will serve on its board of directors along with representatives from three philanthropies: the Laura and John Arnold Foundation, the Peterson Center on Healthcare, and the Gary and Mary West Foundation. Continue reading →